RecruitingPhase 2NCT07168902

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

A Phase 2 Evaluation of the Safety, Ocular Tolerability, and Efficacy of Topical Ophthalmic BL1107 Versus Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Sponsor

Bausch & Lomb Incorporated

Enrollment

228 participants

Start Date

Oct 24, 2025

Study Type

INTERVENTIONAL

Conditions

Glaucoma

Summary

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Phase 2 trial is comparing a new eye drop medication called BL1107 against timolol (a commonly used glaucoma eye drop) in adults with glaucoma or elevated eye pressure (ocular hypertension). The goal is to see if BL1107 lowers eye pressure as effectively or better than timolol, with a good safety profile. **You may be eligible if...** - You have primary open-angle glaucoma or ocular hypertension in both eyes - You are an adult (age requirements confirmed at screening) **You may NOT be eligible if...** - You have a history of orthostatic hypotension (blood pressure drops when you stand up) - You have any active eye disease other than glaucoma or ocular hypertension - You plan to wear contact lenses during the study - You have a condition that prevents pupil dilation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBL1107 Low dose

Dosed twice daily for 28 days.

DRUGBL1107 High dose

Dosed twice daily for 28 days.

DRUGTimolol maleate 0.5%

Dosed twice daily for 28 days.

Locations(14)

Global Research Management, Inc.

Glendale, California, United States

Eye Research Foundation

Newport Beach, California, United States

California Eye Specialist Medical Group, LLC

Pasadena, California, United States

Eye Associates of Fort Myers

Fort Myers, Florida, United States

Levenson Eye Associates

Jacksonville, Florida, United States

Central Florida Eye Associates

Lakeland, Florida, United States

Lee Shettle Eye and Hearing

Largo, Florida, United States

Clayton Eye Clinical Research, LLC

Morrow, Georgia, United States

Coastal Research Associates, LLC

Roswell, Georgia, United States

Heart of America Eye Care

Shawnee Mission, Kansas, United States

Andover Eye Associates

Andover, Massachusetts, United States

Scott & Christie and Associates, PC

Cranberry Township, Pennsylvania, United States

Total Eye Care, P.A.

Memphis, Tennessee, United States

Houston Eye Associates

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07168902

Related Trials

Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry

NCT040242931 location

The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis

NCT042329821 location

Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice

NCT070150342 locations

Defining Retinal Structures Using Hyperspectral Retinal Imaging

NCT075555741 location

Change in IOP Fluctuation After DSLT

NCT074286681 location